

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HIGHLY SPECIALISED TECHNOLOGY EVALUATION PROGRAMME

Equality impact assessment – Guidance development

HST Burosumab for treating X-linked hypophosphataemia [ID1151]

The impact on equality has been assessed during this evaluation according to the principles of the NICE equality scheme.

Consultation

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how? |
|---|

No equalities issues raised at scoping.

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or independent academic report, and, if so, how has the Committee addressed these? |
|--|

The company stated that a refusal to recommend a treatment that principally affects children is discriminatory based on age.
--

The committee took the fact that burosumab would be used for children and young people into consideration when formulating its recommendations.

- | |
|--|
| 3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these? |
|--|

No further issues were identified.

- | |
|--|
| 4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other |
|--|

groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No

7. Have the Committee's considerations of equality issues been described in the evaluation consultation document, and, if so, where?

It is noted in the ECD that no equalities issues were identified. See sections 4.29 and 4.30.

Approved by Associate Director (name): ...Sheela Upadhyaya

Date: 06/06/2018

Final evaluation determination

(when an ECD issued)

1. Have any additional potential equality issues been raised during the

consultation, and, if so, how has the Committee addressed these?
No further issues were identified.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?
Not applicable

5. Have the Committee's considerations of equality issues been described in the final evaluation determination, and, if so, where?
Equalities issues are mentioned in section 4.33 of the FED.

Approved by Centre or Programme Director (name): Helen Knight

Date: 10/10/2018